Evidence map›Paper›PMID 25047444›Full record

ArticleBMB reports2015

Anticancer activity of CopA3 dimer peptide in human gastric cancer cells.

Joon Ha Lee, In-Woo Kim, Sang-Hee Kim, Eun-Young Yun, Sung-Hee Nam, Mi-Young Ahn, Dong-Chul Kang, Jae Sam Hwang

Abstract read
In one paragraph

Article in BMB reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Peptide Fractions Extracted from the Hemolymph ofInternational journal of molecular sciences · 2025
    Article
  2. Article
  3. Application Value of Antimicrobial Peptides in Gastrointestinal Tumors.International journal of molecular sciences · 2023
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Joon Ha LeeDepartment of Agricultural Biology, National Academy of Agricultural Science, RDA, Wanju 565-851, Korea.
In-Woo KimDepartment of Agricultural Biology, National Academy of Agricultural Science, RDA, Wanju 565-851, Korea.
Sang-Hee KimDepartment of Agricultural Biology, National Academy of Agricultural Science, RDA, Wanju 565-851, Korea.
Eun-Young YunDepartment of Agricultural Biology, National Academy of Agricultural Science, RDA, Wanju 565-851, Korea.
Sung-Hee NamDepartment of Agricultural Biology, National Academy of Agricultural Science, RDA, Wanju 565-851, Korea.
Mi-Young AhnDepartment of Agricultural Biology, National Academy of Agricultural Science, RDA, Wanju 565-851, Korea.
Dong-Chul KangIlsong Institute of Life Science, Hallym University, Anyang 431-060, Korea.
Jae Sam HwangDepartment of Agricultural Biology, National Academy of Agricultural Science, RDA, Wanju 565-851, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CopA3 is a homodimeric α-helical peptide derived from coprisin which is a defensin-like antimicrobial peptide that was identified from the dung beetle, Copris tripartitus. CopA3 has been reported to have anticancer activity against leukemia cancer cells. In the present study, we investigated the anticancer activity of CopA3 in human gastric cancer cells. CopA3 reduced cell viability and it was cytotoxic to gastric cancer cells in the MTS and LDH release assay, respectively. CopA3 was shown to induce necrotic cell death of the gastric cancer cells by flow cytometric analysis and acridine orange/ethidium bromide staining. CopA3-induced cell death was mediated by specific interactions with phosphatidylserine, a membrane component of cancer cells. Taken together, these data indicated that CopA3 mainly caused necrosis of gastric cancer cells, probably through interactions with phosphatidylserine, which suggests the potential utility of CopA3 as a cancer therapeutic.

Indexed as

AnimalsAntimicrobial Cationic PeptidesAntineoplastic AgentsCell Line, TumorCell MembraneCell SurvivalHeLa CellsHumansInsect ProteinsMicePhosphatidylserinesRAW 264.7 CellsStomach NeoplasmsAntimicrobial Cationic PeptidesAntineoplastic AgentsCopA3 peptide, Copris tripartitusInsect ProteinsPhosphatidylserines

Identifiers

PMID25047444
PMCPMC4578618

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.